Tango Therapeutics Inc
$ 12.73
4.34%
23 Feb - close price
- Market Cap 1,643,060,000 USD
- Current Price $ 12.73
- High / Low $ 13.60 / 12.31
- Stock P/E N/A
- Book Value 1.43
- EPS -0.91
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -0.52 %
- 52 Week High 13.60
- 52 Week Low 1.03
About
Tango Therapeutics Inc. is a clinical-stage biotechnology company at the forefront of developing targeted therapies to address unmet needs in cancer treatment through innovative approaches, particularly the concept of synthetic lethality. With a diverse pipeline of promising drug candidates, Tango is strategically positioned to lead advancements in precision oncology. The company emphasizes collaborative efforts with prestigious research institutions, bolstering its scientific expertise and expediting the translation of groundbreaking discoveries into effective therapies. Tango's commitment to transforming cancer care reflects its mission to improve patient outcomes and revolutionize treatment paradigms in oncology.
Analyst Target Price
$15.25
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-03-17 | 2024-11-06 | 2024-08-07 | 2024-05-08 | 2024-03-18 | 2023-11-08 | 2023-08-07 | 2023-05-09 | 2023-03-27 |
| Reported EPS | -0.14 | -0.35 | -0.36 | -0.34 | -0.27 | -0.24 | -0.35 | -0.32 | -0.23 | -0.23 | -0.32 | -0.33 |
| Estimated EPS | -0.07 | -0.35 | -0.3459 | -0.3428 | -0.37 | -0.34 | -0.31 | -0.28 | -0.34 | -0.34 | -0.35 | -0.35 |
| Surprise | -0.07 | 0 | -0.0141 | 0.0028 | 0.1 | 0.1 | -0.04 | -0.04 | 0.11 | 0.11 | 0.03 | 0.02 |
| Surprise Percentage | -100% | 0% | -4.0763% | 0.8168% | 27.027% | 29.4118% | -12.9032% | -14.2857% | 32.3529% | 32.3529% | 8.5714% | 5.7143% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.31 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TNGX
2026-02-23 14:24:11
Mizuho has initiated coverage on Tango Therapeutics (NASDAQ:TNGX) with an "outperform" rating and a $19.00 price target, representing a potential 55.7% upside. This follows other brokerage ratings, contributing to a "Moderate Buy" consensus from analysts with an average price target of $15.50. The article also details recent insider stock sales and institutional investment activity in the company.
2026-02-23 10:08:17
Mizuho has initiated coverage on Tango Therapeutics (NASDAQ:TNGX) with an outperform rating and a $19.00 price target, citing the potential of its lead precision oncology program, vopimetostat. The stock, currently trading at $12.20, has seen a 417% return over the past year. The firm anticipates significant outperformance driven by positive Phase I readouts in 2026 and expects $1.8 billion in risk-adjusted worldwide vopimetostat sales by 2035.
2026-02-19 08:57:48
Tango Therapeutics (TNGX) is set to release its Q4 2025 earnings before market open on February 26th, with analysts forecasting an EPS of ($0.31). The company, trading at $12.41, has a "Moderate Buy" consensus rating and a target price of $14.80. Recent insider selling activity by Adam Crystal and CFO Daniella Beckman has been noted, while institutional investors have adjusted their stakes in the company.
2026-02-18 18:57:48
Tango Therapeutics (NASDAQ: TNGX) announced it will release its fourth-quarter 2025 financial results on March 5, 2026, without a conference call. Additionally, the company will participate in three investor conferences in March: the TD Cowen 46th Annual Health Care Conference, the Barclays 28th Annual Global Healthcare Conference, and the Leerink Partners Global Healthcare Conference. Webcasts of these events will be available on the company's website.
2026-02-18 17:19:08
Tango Therapeutics announced it will report Q4 2025 financial results on March 5, 2026, and will participate in three upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference, Barclays 28th Annual Global Healthcare Conference, and Leerink Partners Global Healthcare Conference. The company, a clinical-stage biotechnology firm focused on precision cancer medicine, will provide webcasts for these events.
2026-02-18 12:27:41
Tango Therapeutics (NASDAQ: TNGX) announced it will report its fourth quarter 2025 financial results on March 5, 2026, before the U.S. financial markets open. The company also confirmed its management will participate in three upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference, the Barclays 28th Annual Global Healthcare Conference, and the Leerink Partners Global Healthcare Conference, taking place between March 4 and March 11, 2026. Live webcasts and replays for these events will be available on the company's website.
